Best Cancer Hospitals in China 2025

Best Cancer Hospitals in China

China has become a world leader in medical innovation, especially in oncology. The nation has, over the past decade, made tremendous progress in biotechnology, focusing heavily on immunotherapy, targeted therapy, and cell and gene therapy. Spurred by government funding, top-notch institutions, and state-of-the-art research, China now has one of the most sophisticated cancer hospitals in the world.

This article investigates China’s leading cancer hospitals, their expertise, their contributions to global clinical trials, and their cell and gene therapy—particularly CAR T-cell therapy for both hematologic malignancies and solid tumors. Whether you or your loved one needs cutting-edge cancer treatment, continue reading to find out where innovations occur daily.

Why China is Leading in Cancer Care

China’s growing prominence in cancer care stems from several key factors:

• Massive investment in biotechnology infrastructure

• Active participation in international clinical trials

• Rapid development of CAR T-cell therapy and other cell-based treatments

• Integrated approach combining Western medicine and Traditional Chinese Medicine (TCM)

• Global partnerships and talent recruitment

With more than 5 million new cancer cases annually, China has developed a robust healthcare ecosystem to tackle this burden. Hospitals across the nation are equipped with the latest technologies like proton therapy, robotic surgeries, AI-based diagnostics, and next-generation sequencing.

Cancer Clinical Trials in China: Accelerating Innovation

China is currently among the leading nations in performing clinical trials, particularly in oncology. Based on ClinicalTrials.gov data, there are thousands of trials for cancer, with many targeting new immunotherapies and CAR T-cell therapy for blood cancers and solid tumors.

In China, institutions have worked together with biotech firms worldwide to experiment with PD-1/PD-L1 inhibitors, bispecific antibodies, and tumor-infiltrating lymphocytes (TILs). The relentless quest for new therapies has made Chinese cancer hospitals a travel destination for patients from all over Asia, the Middle East, and even Europe.

Cell and Gene Therapy in China: The CAR T Revolution

CAR T-cell therapy, a form of personalized immunotherapy, has become a major focus for Chinese researchers and clinicians. China is one of the largest contributors to global CAR T clinical trials, especially for:

• Hematological malignancies: B-cell leukemia, lymphoma, and multiple myeloma

• Solid tumors: Lung, liver, pancreatic, and ovarian cancers

Chinese hospitals are now integrating dual-target CAR T therapies, armored CAR T cells, and allogeneic “off-the-shelf” approaches. This trend has led to higher remission rates, even in refractory cases.

Top Cancer Hospitals in China

Here’s a comprehensive list of the best hospitals for cancer treatment in China, each playing a pivotal role in patient care and research.

1. Fudan University Shanghai Cancer Center

One of China’s oldest and most prestigious cancer hospitals, Fudan’s center is a leader in breast, lung, colorectal, and liver cancer care. It also has robust clinical trials in immunotherapy and chemotherapy. The hospital is a hub for precision medicine and translational oncology.

2. Shanghai Cancer Hospital

Renowned for its multidisciplinary care, Shanghai Cancer Hospital offers advanced treatment protocols and has one of the largest patient volumes in Asia. It is a leader in integrating radiotherapy and systemic treatments.

Shanghai Cancer Hospital

3. Beijing Gobroad Hospital

Beijing Gobroad is known for CAR T-cell therapy and gene editing research. With a focus on hematological cancers, the hospital is also a training center for emerging biotech professionals and a site for international clinical trials.

Beijing Gobroad Hospital

4. Tianjin Cancer Hospital Airport Hospital

This institution stands out for its specialization in thoracic and gastrointestinal cancers. It also has a sophisticated imaging center for early cancer detection and precision diagnostics.

Tianjin Cancer Hospital

5. Nanfang-Chunfu Children’s Institute of Hematology & Oncology

Dedicated to pediatric cancers, this hospital offers cutting-edge care for leukemia, lymphoma, and neuroblastoma. It is part of several global pediatric oncology collaborations.

Nanfang-Chinfu Children’s Institute of Hematology and Oncology

6. Beijing Boren Hospital

Boren Hospital excels in integrative oncology, combining Traditional Chinese Medicine (TCM) with modern protocols. It offers personalized treatment strategies for late-stage cancers and pain management.

Beijing Boren Hospital

7. Jiahui International Hospital

A state-of-the-art facility in Shanghai, Jiahui caters to international patients. It provides comprehensive cancer care, including molecular diagnostics, chemotherapy, radiation, and supportive care.

Jiahui Cancer Hospital

8. The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

This university hospital is a leader in translational cancer research and next-generation sequencing (NGS)-guided treatments. It has extensive clinical trials in targeted therapies and immuno-oncology.

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

9. Beijing Puhua International Hospital

Puhua specializes in neuro-oncology and brain tumors. Its innovative protocols include stem cell therapy, CyberKnife radiosurgery, and minimally invasive interventions.

Puhua International Hospital

10. Beijing Tiantan Hospital

Originally known for neurosurgery, Tiantan has expanded into oncology with specialized centers for brain tumors and spine cancers. Its neuro-oncology division is among the best in Asia.

Beijing Tiantan Hospital

11. Beijing Jingdu Children’s Hospital

Focusing on childhood cancers, this hospital provides multidisciplinary pediatric oncology care with access to CAR T-cell therapy for leukemia and lymphoma in young patients.

Jingdu Children’s Hospital

12. Institute of Hematology and Blood Diseases, Tianjin

This institute is a national reference center for hematologic cancers. It plays a major role in CAR T-cell development, stem cell transplants, and gene editing research.

Institute of Hematology and Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

13. Peking University Cancer Hospital

With world-class departments in breast, colorectal, and gastric cancers, this hospital conducts hundreds of clinical trials yearly. Its precision medicine platform supports genomic profiling for every cancer patient.

Peking University Cancer Hospital

14. Shenzhen Cancer Hospital, Chinese Academy of Medical Sciences

An academic and clinical powerhouse, this hospital combines cancer research with elite clinical services, especially in lung, breast, and liver cancers.

Shenzen Cancer Hospital

15. Shenzhen University General Hospital

The hospital’s cancer center is known for its collaborations with international biotech firms. It is also a trial site for new targeted therapies in EGFR-mutated and ALK-positive lung cancers.

16. Hong Kong University Shenzhen Hospital

This hospital bridges Hong Kong’s medical system and mainland China. It offers advanced imaging, robotic surgery, and international clinical trial access for patients in southern China.

Hong Kong University Shenzen Hospital

17. Sun Yat-Sen University Cancer Center (SYSUCC)

One of the most respected cancer hospitals in Asia, SYSUCC is involved in large-scale CAR T trials, checkpoint inhibitor studies, and drug discovery. Its pancreatic and nasopharyngeal cancer programs are world-renowned.

Sun Yat-Sen University Cancer Hospital

18. Southern Medical University of Integrated Traditional Chinese and Western Medicine

This unique institution promotes holistic oncology care. It uses acupuncture, herbal medicine, and dietary therapy alongside modern chemotherapy and immunotherapy.

Southen medical university of integrated Traditional Chinese and Western Medicine

19. Henan Tumor Hospital

Serving central China, this hospital is known for colorectal and liver cancer programs. It is also a key site for CAR T-cell therapy trials in multiple myeloma and B-cell lymphomas.

20. Tiantan Hospital

In addition to its neuro-oncology reputation, Tiantan Hospital is expanding its footprint in glioblastoma and CNS lymphoma treatment trials using targeted therapies.

Tiantan Hospital

Cost of Cancer Treatment in China

Compared to Western nations, the cost of cancer treatment in China is significantly lower—often 50–70% less for similar treatments. This includes:

• Chemotherapy and radiotherapy

• Surgical procedures

• Targeted therapies and immunotherapies

• CAR T-cell therapy

While costs vary based on hospital and treatment complexity, the affordability and quality of care in China make it an attractive destination for international patients.

Why Choose Cancer Treatment in China?

• Access to the latest cancer innovations

• Affordable costs compared to US or Europe

• Global standard of care

• Multilingual medical staff in top international hospitals

• World-leading clinical trial programs

Whether you’re looking for early-stage diagnostics or advanced cancer care, China’s hospitals offer comprehensive, state-of-the-art solutions.

Connect With CancerFax for Advanced Cancer Treatment in China

Navigating cancer treatment abroad can be overwhelming. That’s where CancerFax comes in.

We help patients connect with top cancer hospitals in China and provide end-to-end support, including:

• Treatment planning and hospital selection

• Cost estimates and travel logistics

• Access to clinical trials and CAR T-cell therapy

• Pick-up and drop-off to the nearest airport

• Local language support and follow-up care

👉 Contact CancerFax today to book an appointment and explore cancer treatment options in China.

Visit www.cancerfax.com or email us at info@cancerfax.com to get started.

China is no longer just an emerging player in cancer treatment—it is a global leader. With some of the best hospitals for cancer treatment, cutting-edge therapies, and a thriving biotech ecosystem, it offers hope for patients worldwide. Whether you are seeking innovative immunotherapy or looking to enroll in a clinical trial, China is where science meets compassion.

Explore your options. Choose wisely. Choose healing.

Susan Hau

Website |  + postsBio ⮌

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

• Susan Hau

  https://cancerfax.com/author/susan/

  Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
• Susan Hau

  https://cancerfax.com/author/susan/

  Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
• Susan Hau

  https://cancerfax.com/author/susan/

  Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
• Susan Hau

  https://cancerfax.com/author/susan/

  Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer